Rheumatoid factors do not predict cardiovascular disease and mortality in the general population in the Busselton Health Survey

Johannes Nossent 1,2*, Warren Raymond 1, Mark Divitini 3 and Matthew Knuiman 3,4

Abstract

Background: Rheumatoid Factors (RF) are antibodies directed against the Fc portion of IgG and are involved in clearance of immune complexes. While RF can develop in a wide range of conditions, higher RF levels indicate a greater risk for a severe disease course in Rheumatoid Arthritis (RA) patients including cardiovascular complications and premature death. We investigated whether RF also constitute a risk factor for these outcomes in the general population.

Methods: We included 2,323 participants (46% male, mean age 50 years) free of CVD at baseline in 1972. RF positivity was defined as a score of ≥2 by latex agglutination (scale 0–5). All outcomes during 42-year follow-up were obtained from state-wide registries. The predictive value of RF for coronary heart disease, all cardiovascular disease and all-cause mortality was estimated by adjusted hazard ratios (HR) from Cox regression models.

Results: After adjustment for standard risk factors, RF positivity was not predictive of future CHD (HR 1.05, p = 0.61), CVD (HR 1.04, p = 0.63) or mortality (HR 1.03, p = 0.70) in the full CVD-free cohort. In an interaction model, RF in 41 out of 355 participants with an RA history was not predictive of CHD (HR 0.92, p = 0.77) or CVD events (HR 1.15, p = 0.51), but there was a borderline significant association with overall mortality (HR 1.41, CI 0.97–2.04, p = 0.07).

Conclusions: RF detected by Latex agglutination do not independently predict future CHD, CVD or death in the general population. However, the presence of RF in the context of a history of RA is associated with a moderate, borderline significant increase in the long term adjusted risk for all-cause mortality.

Keywords: Rheumatoid factors, Cardiovascular disease, Mortality, Rheumatoid arthritis

Background

Rheumatoid Factors (RF) are a family of polyclonal antibodies directed against the Fc portion of IgG [1]. The functions of RF include immune complex (IC) clearance, complement fixation and antigen uptake by B cells for T cell presentation. The origin of RF is not well understood, but they can be induced bacterial lipopolysaccharides and Epstein-Barr virus [2–5]. The overall evidence points to RF development as part of normal host defense mechanism that involves an immune response to modified IgG. Consequently, RF are prevalent in a range of inflammatory conditions including Rheumatoid Arthritis (RA), where RF presence increases the risk for bony joint erosions, accelerated atherosclerosis, cardiovascular disease (CVD) and early mortality [6, 7]. Despite its inherent low specificity, RF testing is widely used as a screening test for rheumatic disease. It is unclear whether the incidental presence of RF in non-RA individuals reflects a state of chronic inflammation, which is a recognized risk factor for atherosclerosis [8]. RF as detected by Waaler-Rose assay was a risk factor for future coronary heart disease (CHD) as well as overall mortality in the general population of Iceland [9]. We investigated
whether RF as detected by a routine Latex agglutination assay also indicate an increased risk for CHD, CVD and death in a community based cohort of Australian adults with long-term follow-up.

**Methods**

**Study design and participants**

Cross-sectional surveys were conducted in the district of Busselton in Western Australia (WA) every 3 years from 1966 to 1981 [10]. For this study the cohort was all adults who attended the 1972 survey and who were also tested for RF in the 1969 survey. Over 95% of the cohort were of Caucasian background. All participants gave informed consent and the surveys and this analysis were approved by the The Human Research Ethics Committee of the Department of Health of WA.

**Baseline measurements and follow-up outcome events**

All baseline data for this cohort of participants was taken from the 1972 survey except for RF status which came from serum collected in the 1969 survey. In the 1972 survey, participants completed a baseline health and lifestyle questionnaire on smoking, diabetes, anti-hypertensive treatment, doctor-diagnosed RA, angina pectoris and myocardial infarction. Those with a history of CHD (based on Rose questionnaire and ECG) or stroke were excluded [10]. Blood pressure was measured by a mercury sphygmomanometer after five minutes rest in a sitting position. Serum collected in the 1969 survey was assayed for RF by latex-agglutination (Hyland, USA) with results semi quantitatively graded from 0 (negative) to 5 (strongly positive) with all scores $\geq 1$.

Results from serum collected in the 1969 survey. In the 1972 survey except for RF status which came from serum collected in the 1969 survey. Over 95% of the cohort were of Caucasian background. All participants gave informed consent and the surveys and this analysis were approved by the The Human Research Ethics Committee of the Department of Health of WA.

**Statistical analysis**

Results presented are for the cohort with no history of CHD or stroke at baseline in 1972. Cox regression models for time from baseline to first outcome event were used to obtain adjusted hazard ratios (with 95% confidence intervals) for history of RA (yes, no) and for RF considered both as a continuous score (values 0 to 5) to provide the trend test $p$-value and also as a binary variable (negative 0–1, positive 2–5). We formed the RF groups of 0–1 and 2–5 because the distribution of RF score was uneven with 1778 people with score 0, 190 with score 1, 182 with score 2, 118 with score 3, 54 with score 4 and 1 with score 5 and the number of outcome events was less than 100 for many of the groups from 1 to 5. Two models were fitted, the first adjusted for age and sex only (Additional file 1: Tables S1 and S2), and the second adjusted for age, sex, smoking, BMI, SBP, hypertension medication, cholesterol, and diabetes (Tables 2 and 3). Results from Cox regression models are presented as estimated hazard ratios (with 95% confidence interval and $p$-value). The proportional hazards assumptions for the effects of RF and RA on outcomes were tested via an interaction with follow-up time and in all cases the assumption was not violated (with interaction $p$-values ranging from 0.318 to 0.859).

**Results**

The study cohort included 2323 participants free of CHD or stroke at baseline. RF prevalence was 15.3% at the chosen cut-off level of $\geq 2$. Table 1 shows the descriptive statistics for the cohort by RF status, RA status and overall. The cohort has a behavioural and biomedical risk factor profile typical of the general population at that time [10].

As results from the model that adjusted for age and sex only (Additional file 1: Tables S1 and S2) were essentially the same as the results from the fully adjusted model (Tables 2 and 3), only results from the fully adjusted models are described here. The presence of RF or a history of RA, when considered separately or together (i.e. adjusted for the other) were not predictive of CHD or CVD events (all $p$-values > 0.3) (Table 2). A positive RF was associated with a 5% increased risk of CHD events (HR 1.05, 95% CI 0.87–1.28, $p = 0.61$) and a 4% increased risk of CVD events (HR 1.04, 95% CI 0.89–1.21, $p = 0.63$). A doctor diagnosis of RA was associated with a 1% increased risk of CHD events (HR 1.01, 95% CI 0.79–1.28, $p = 0.94$) and CVD events (HR 1.01, 95% CI 0.83–1.22, $p = 0.95$). Similarly, the presence of RF or a history of RA were not associated with all-cause mortality (all $p$-values >0.5) (Table 3). A positive RF was associated with a 3% increased risk of death (HR 1.03, 95% CI 0.89–1.19, $p = 0.70$) and a doctor diagnosis of RA was associated with a 0% increased risk of death (HR 1.00, 95% CI 0.84–1.19, $p = 0.99$). Increasing the cut-off level for RF positivity to an agglutination score $\geq 3$ or $\geq 4$
decreased the prevalence of RF to 7.4 and 2.2%, but did not change any of the follow-up results markedly.

Models that included an interaction between RF and history of RA showed that the effect of RF on CHD events (interaction $p = 0.62$) and CVD events (interaction $p = 0.61$) was not significantly different in people with and without a history of RA (Table 2). In people with a history of RA, a positive RF was associated with an 8% decreased risk of CHD events (HR 0.92, 95% CI 0.51–1.64, $p = 0.77$) and a 15% increased risk of CVD events (HR 1.15, 95% CI 0.75–1.77, $p = 0.51$). However, in relation to all-cause mortality, the interaction between RF and history of RA approached significance ($p = 0.075$). In people with a history of RA, a positive RF was associated with a 41% increased risk of death (HR 1.41, 95% CI 0.97–2.04, $p = 0.069$).

Table 1  Descriptive statistics for the cohort free of CHD and stroke at baseline in 1972. Table shows mean (SD), percent or $N$ (%)

| Characteristic or measure | RF 0–1 ($n = 1968$) | 2–5 ($n = 355$) | RA No ($n = 2124$) | Yes ($n = 199$) | Total ($n = 2323$) |
|--------------------------|---------------------|----------------|-------------------|----------------|------------------|
| Male (%)                 | 48.9                | 31.5           | 47.0              | 38.2           | 46.3             |
| Age (years)              | 49.2 (14.4)         | 55.6 (14.2)    | 49.4 (14.6)       | 57.8 (12.5)    | 50.1 (14.6)      |
| Smoking                  |                     |                |                   |                |                  |
| Never (%)                | 47.5                | 53.0           | 48.1              | 51.3           | 48.3             |
| Ex (%)                   | 22.9                | 21.4           | 22.7              | 21.6           | 22.6             |
| Current (%)              | 29.6                | 25.6           | 29.2              | 27.1           | 29.0             |
| Smoking                  |                     |                |                   |                |                  |
| BMI (kg/m$^2$)           | 25.1 (3.6)          | 25.1 (3.6)     | 25.1 (3.6)        | 25.6 (4.2)     | 25.1 (3.6)       |
| Systolic BP (mm Hg)      | 136 (20)            | 139 (22)       | 135 (20)          | 143 (23)       | 136 (21)         |
| Diastolic BP (mm Hg)     | 78 (13)             | 80 (12)        | 78 (13)           | 81 (12)        | 79 (13)          |
| Hypertension medication (%) | 6.6                 | 11.5           | 6.9               | 12.6           | 7.4              |
| Cholesterol (mmol/L)     | 6.33 (1.24)         | 6.58 (1.37)    | 6.34 (1.24)       | 6.58 (1.46)    | 6.36 (1.27)      |
| Diabetes mellitus (%)    | 1.7                 | 2.3            | 1.6               | 4.0            | 1.8              |
| History of Rheumatoid Arthritis (%) | 8.0              | 11.5           | -                 | -              | 8.6              |
| Rheumatoid Factor        |                     |                |                   |                |                  |
| Score (0–5)              | 0.10 (0.30)         | 2.65 (0.74)    | 0.47 (0.98)       | 0.67 (1.18)    | 0.49 (1.00)      |
| Positive (2–5) (%)       | -                   | -              | 14.8              | 20.6           | 15.3             |
| Follow-up time (years)   | 26.1 (13.9)         | 22.1 (14.0)    | 26.0 (14.0)       | 20.0 (13.2)    | 25.5 (14.0)      |
| No. with CHD event       | 647 (32.9)          | 128 (36.1)     | 699 (32.9)        | 76 (38.2)      | 775 (33.4)       |
| No. with CVD event       | 1005 (51.1)         | 207 (58.3)     | 1089 (51.3)       | 123 (61.8)     | 1212 (52.2)      |
| No. of deaths            | 1141 (58.0)         | 241 (67.9)     | 1229 (57.9)       | 153 (76.9)     | 1382 (59.5)      |

Table 2  Estimated adjusted hazard ratios for rheumatoid factor (RF) and rheumatoid arthritis (RA) in relation to CHD and CVD events in the cohort free of CHD and stroke at baseline in 1972. Table shows hazard ratio, 95% CI and $p$-value

| Risk factor | CHD | CVD |
|-------------|-----|-----|
| RA (not adjusted for RF) | HR* (95% CI) 1.01 (0.79, 1.28) | p-value 0.943 | HR* (95% CI) 1.01 (0.83, 1.22) | p-value 0.950 |
| RA (adjusted for RF) | HR* (95% CI) 1.01 (0.79, 1.28) | p-value 0.951 | HR* (95% CI) 1.01 (0.83, 1.21) | p-value 0.953 |
| RF score* (not adjusted for RA) | HR* (95% CI) 1.02 (0.95, 1.10) | p-value 0.522 | HR* (95% CI) 1.03 (0.97, 1.09) | p-value 0.352 |
| RF score* (adjusted for RA) | HR* (95% CI) 1.02 (0.95, 1.10) | p-value 0.523 | HR* (95% CI) 1.03 (0.97, 1.09) | p-value 0.352 |
| RF positive (not adjusted for RA) | HR* (95% CI) 1.05 (0.87, 1.28) | p-value 0.610 | HR* (95% CI) 1.04 (0.89, 1.21) | p-value 0.633 |
| RF positive (adjusted for RA) | HR* (95% CI) 1.05 (0.87, 1.28) | p-value 0.611 | HR* (95% CI) 1.04 (0.89, 1.21) | p-value 0.633 |
| RF positive (for RA = no) | HR* (95% CI) 1.07 (0.87, 1.31) | p-value 0.516 | HR* (95% CI) 1.02 (0.87, 1.20) | p-value 0.787 |
| RF positive (for RA = yes) | HR* (95% CI) 0.92 (0.51, 1.64) | p-value 0.770 | HR* (95% CI) 1.15 (0.75, 1.77) | p-value 0.512 |

*From Cox model adjusted for age, sex, smoking, BMI, SBP, hypertension medication, cholesterol and diabetes

*HR is for an increase of one in the score

*From Cox model that included interaction between RF and RA
**Table 3** Estimated adjusted hazard ratios for rheumatoid factor (RF) and rheumatoid arthritis (RA) in relation to Death (any cause) in the cohort free of CHD and stroke at baseline in 1972. Table shows hazard ratio, 95% CI and p-value.

| Risk factor                          | HR* (95% CI) | p-value |
|-------------------------------------|--------------|---------|
| RA (not adjusted for RF)            | 1.00 (0.84, 1.18) | 0.994   |
| RA (adjusted for RF)                | 1.00 (0.84, 1.18) | 0.995   |
| RF score (not adjusted for RA)      | 1.01 (0.96, 1.07) | 0.590   |
| RF score (adjusted for RA)          | 1.01 (0.96, 1.07) | 0.590   |
| RF positive (not adjusted for RA)   | 1.03 (0.89, 1.19) | 0.698   |
| RF positive (adjusted for RA)       | 1.03 (0.89, 1.19) | 0.698   |
| RF positive (for RA = no)           | 0.98 (0.84, 1.14) | 0.785   |
| RF positive (for RA = yes)          | 1.41 (0.97, 2.03) | 0.069   |

*From Cox model adjusted for age, sex, smoking, BMI, SBP, hypertension medication, cholesterol and diabetes

**Discussion**

This population based cohort study with long-term follow-up found a significant population prevalence of RF as detected by latex agglutination, but no evidence that RF or having a history of RA in itself were independent risk factors for CHD, CVD events or all-cause mortality. Only the presence of RF in patients with a history of RA was associated with an increase in long term mortality risk.

Using moderately strict cut-off levels for RF positivity, we found a high prevalence of RF at 15% in this Western Australian population. Increasing cut-off levels understandably reduced the prevalence of RF to 7.4% (at cut-off ≥3) and 2.2% (at cut-off ≥4), but despite the presumed increase in specificity, the use of different cut-off levels did not significantly change the overall risks for CVD or death. Our results are largely in agreement with findings in an earlier population study performed in Iceland [9], where RF as measured by latex agglutination was present in almost 11% of the participants, but had no predictive value for coronary heart disease or death during a median follow-up of 23 years. Interestingly, in the Icelandic study a subgroup of latex RF positive individuals tested positive (titre ≥1:10) by the Waaler–Rose (WR) erythrocyte agglutination assay, which is an assay with significantly higher specificity for RA. Even though the assays in the two studies are not directly comparable, the WR positive patients in the Icelandic study form a realistic approximation of our RA cohort. Under this assumption, the fully adjusted HR for overall mortality of 1.40 (1.14 to 1.72) for WR positive participants in the Icelandic study fits well with the HR of 1.41 (0.97–2.03) for participants reporting RA in this cohort (Table 3).

While the exact biological properties of RF that lead to the associated risks for joint erosions and accelerated atherosclerosis in RA patients are not well defined, this could involve affinity maturation of the RF response, which under the influences of endo- and exogenous triggers occurs through accumulated somatic mutations in RF producing autoreactive B cells clones [13, 14]. The more stringent conditions in the Waaler-Rose assay capture this underlying process better than the Latex agglutination for RF detection. The limitations of this study include the use of patient reported, but doctor-diagnosed RA at a time in history where there was limited clinical experience with RF testing. Also, there is a possibility that RF effects are too small for this study to detect. A power calculation showed a 90% power to detect a HR of 1.32 for RF (positive vs. negative) in relation to CHD events and a HR of 1.25 in relation to CVD events. The long follow up period, the ability to use different RF cut-off levels and to fully adjust for traditional risk factors as well the completeness of outcome capturing provide considerable strength to this study.

**Conclusions**

RF as detected by Latex agglutination do not independently predict cardiovascular disease or death in the general population. These data provide reassurance for physicians faced with a false positive RF test detected by latex agglutination.

**Additional file**

Additional file 1: Additional data on RF as predictor of CHD, CVD and death. Tables showing the estimated adjusted hazard ratios for rheumatoid factor (RF) and rheumatoid arthritis (RA) presence in the cohort free of CHD and stroke at baseline in 1972 in relation to Subsequent CHD and CVD events (Table S1), Subsequent death (any cause) (Table S2). (DOCX 17 kb)

**Abbreviations**

BHS: Busselton health survey; BMI: Body mass index; CI: Confidence interval; CRP: C-reactive protein; CVD: Cardiovascular disease; CVE: Cardiovascular events; HMDS: Western Australian hospital morbidity data collection; HR: Hazard ratio; IC: Immune complex; IC: International classification of diseases; RA: Rheumatoid arthritis; RF: Rheumatoid factors; SBP: Systolic blood pressure; WA: Western Australia

**Acknowledgments**

The authors thank the Arthritis Foundation of WA for their generous support and the staff at the Western Australian Data Linkage Branch, the Department of Health Inpatient Data Collection and Registrar General for extraction and provision of linked data. We are grateful to the Busselton Population Medical Research Institute for permission to use the survey data and the community of Busselton for their long-standing support of the Busselton Health Study.

**Funding**

This study was supported by an unrestricted grant from The Arthritis Foundation of Western Australia. The 1994/95 Busselton Health Survey was supported by the Health Promotion Foundation of Western Australia. The construction of the linked data file was supported by an NHMRC project Grant (404022).
Busselton Health Study, please contact Professor Matthew Knuiman (mail to:matthew.knuiman@uwa.edu.au). For information regarding data sharing of Western Australian Data Linkage Records please contact the WA Data Linkage Branch at the Department of Health, Western Australia.

Authors’ contributions
All named authors were involved in this project. JC conceived and designed the study, provided methodological advice, participated in data interpretation and wrote the first and final draft of the manuscript. WR assisted with study design and data analysis, performed literature study and critically reviewed manuscript. MD performed data extraction and analyses and critically reviewed manuscript. MK provided guidance with study design, supervised data extraction and analysis and critically reviewed final manuscript in his role as data custodian of Busselton Health Survey. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
This data analysis was approved by the Human Research Ethics Committee of the Department of Health of WA.

Ethics approval and consent to participate
The Human Research Ethics Committee of the Department of Health of WA approved the BHS and WA-HMDC record linkage. All participants gave Ethics approval and consent to participate of the Department of Health of WA.

This data analysis was approved by the Human Research Ethics Committee of the Department of Health of WA.

Consent for publication
The authors declare that they have no competing interests.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1School of Medicine & Pharmacology, The University of Western Australia, 35 Stirling Hwy (MS03), Crawley, WA 6009, Australia. 2Department of Rheumatology, Sir Charles Gardiner Hospital, Perth, WA, Australia. 3School of Population Health, The University of Western Australia, Perth, WA, Australia. 4School of Medicine & Pharmacology, The University of Western Australia, 35 Stirling Hwy (MS03), Crawley, WA 6009, Australia. 5Department of Rheumatology, Sir Charles Gardiner Hospital, Perth, WA, Australia. 6School of Population Health, The University of Western Australia, Perth, WA, Australia. 7Busselton Population Medical Research Institute, Busselton, WA, Australia.

Received: 9 September 2016 Accepted: 22 May 2017
Published online: 26 May 2017

References
1. Koopman WJ, Schonenhöfer RE. Rheumatoid factor diversity. In vivo. 1988;2(1):73–7.
2. Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM. 2010;103(3):139–48.
3. Sohy A, Hay FC, Bond A, Asford J, Jones MG, Randen I, et al. The binding of synovial tissue-derived human monoclonal immunoglobulin M rheumatoid factor to immunoglobulin G preparations of differing galactose content. Scand J Immunol. 1994;40(2):135–43.
4. Brown PB, Nardella FA, Mannik M. Human complement activation by self-associated IgG rheumatoid factors. Arthritis Rheum. 1982;25(9):1101–7.
5. Roosnek E, Lanavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med. 1991;173(2):487–9.
6. Ajeganova S, Humphreys JH, Verheul MK, van Steenbergen HW, van Nies JA, Hafstrom I, et al. Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. Ann Rheum Dis. 2016; doi:10.1136/annrheumdis-2015-208579.
7. Humphreys JH, van Nies JA, Chiping J, Marshall T, van der Helm-van Mil AH, Symmons DP, et al. Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Res Ther. 2014;16(6):489.
8. Strong F, Schunkert H. Reactive protein and coronary heart disease: all said–is not it? Mediat Inflamm. 2014;25:7123.
9. Tomasson G, Aspelund T, Jonsson T, Valdimarsson H, Felson DT, Guðnason V. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis. 2010;69(9):1649–54.
10. Knuiman MW, Jamrozik K, Welborn TA, Bulsara MK, Divitini ML, Whitall DE. Age and secular trends in risk factors for cardiovascular disease in Busselton. Aust J Public Health. 1995;19(4):375–82.
11. Hooper B, Whittingham S, Mathews JD, Mackay IR, Cumow DH. Autoimmunity in a rural community. Clin Exp Immunol. 1972;12(1):79–87.
12. Holmen CD, Bass AJ, Rossm D, Smith MB, Simmons JB, Glasson EJ, et al. A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system. Aust Health Rev. 2008;32(4):766–77.
13. Williams DG, Moyes SP, Mageed RA. Rheumatoid factor isotype switch and somatic mutation variants within rheumatoid arthritis synovium. Immunology. 1999;98(1):129–36.
14. Lakov R, Yahud V, Hamo R, Steinitz M. Preferential targeting of somatic hypermutation to hotspot motifs and hypermutable sites and generation of mutational clusters in the IgVH alleles of a rheumatoid factor producing lymphoblastoid cell line. Mol Immunol. 2011;48(5):733–45.